In the context of ovarian cancer, IFNγ in combination with cyclophosphamide and cisplatin significantly prolongs progression‐free survival.50 Moreover, there are 8 ongoing clinical trials involving IFNγ alone or in combination with other anticancer drugs up to now (Table 1). This evidence concerns the gene IFNG and ovarian carcinoma.